ArticleAntimicrobial agents and chemotherapy2003
Activity of and resistance to moxifloxacin in Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Profile of microbial keratitis after corneal collagen cross-linking.BioMed research international · 2014Trial
- Post-fluoroquinolone treatment molecular events and nutrient availability modulatebioRxiv : the preprint server for biology · 2025Article
- Article
- Dynamic category-sensitive hypergraph inferring and homo-heterogeneous neighbor feature learning for drug-related microbe prediction.Bioinformatics (Oxford, England) · 2024Article
- Efflux pump inhibitory potential of indole derivatives as an arsenal againstMicrobiology spectrum · 2023Article
- Prevalence and mechanisms of linezolid resistance among staphylococcal clinical isolates from Egypt.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.Antimicrobial agents and chemotherapy · 2017Article
- Efficacy of antibiotic treatment of implant-associatedDrug design, development and therapy · 2017Article
- Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.The Journal of antimicrobial chemotherapy · 2013Article
- Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.Antimicrobial agents and chemotherapy · 2012Article
- In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.Antimicrobial agents and chemotherapy · 2011Article
- Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.The Journal of antimicrobial chemotherapy · 2010Article
- Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.Antimicrobial agents and chemotherapy · 2008Article
- Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.Clinical ophthalmology (Auckland, N.Z.) · 2008Article
- In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.Antimicrobial agents and chemotherapy · 2007Article
- Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2007Article
- Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.Antimicrobial agents and chemotherapy · 2007Article
- Moxifloxacin in the treatment of skin and skin structure infections.Therapeutics and clinical risk management · 2006Article
- The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.Antimicrobial agents and chemotherapy · 2006Article
- DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.Antimicrobial agents and chemotherapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Moxifloxacin has enhanced potency against Staphylococcus aureus, lower propensity to select for resistant mutants, and higher bactericidal activity against highly resistant strains than ciprofloxacin. Despite similar activity against purified S. aureus topoisomerase IV and DNA gyrase, it selects for topoisomerase IV mutants, making topoisomerase IV the preferred target in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.